Robert A. Belderbos

High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients

Luca Cantini, Federica Pecci, Daan P. Hurkmans et al. · European Journal of Cancer · 2020 · 113 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 84 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Robert A. Belderbos, Rossana Berardi, Robin Cornelissen et al. · Translational Lung Cancer Research · 2019 · 58 citations · Full text

Life Sciences, Immunology, Oncology +17

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

Job P. van Kooten, Robert A. Belderbos, Jan H. von der Thüsen et al. · Thorax · 2022 · 41 citations · Full text

Medicine, Oncology, Pathology +17